FY2024 Earnings Forecast for Femasys Issued By HC Wainwright

Femasys Inc. (NASDAQ:FEMY) – Investment analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Femasys in a report issued on Tuesday, November 12th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($0.84) per share for the year, down from their prior forecast of ($0.78). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Femasys’ Q4 2024 earnings at ($0.22) EPS, FY2025 earnings at ($0.42) EPS, FY2026 earnings at ($0.23) EPS, FY2027 earnings at ($0.19) EPS and FY2028 earnings at ($0.04) EPS.

Femasys (NASDAQ:FEMY) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The firm had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Separately, Chardan Capital reduced their target price on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday.

Femasys Stock Performance

Shares of FEMY opened at $0.98 on Friday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 5.93 and a current ratio of 3.94. The stock has a 50 day moving average price of $1.16 and a two-hundred day moving average price of $1.15. The firm has a market capitalization of $22.44 million, a P/E ratio of -1.21 and a beta of -2.83. Femasys has a 52 week low of $0.73 and a 52 week high of $2.40.

Hedge Funds Weigh In On Femasys

An institutional investor recently bought a new position in Femasys stock. Aljian Capital Management LLC bought a new position in shares of Femasys Inc. (NASDAQ:FEMY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 24,768 shares of the company’s stock, valued at approximately $27,000. Aljian Capital Management LLC owned approximately 0.11% of Femasys at the end of the most recent reporting period. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.